Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information

被引:49
作者
Bacher, U [1 ]
Haferlach, T [1 ]
Kern, W [1 ]
Hiddemann, W [1 ]
Schnittger, S [1 ]
Schoch, C [1 ]
机构
[1] Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, Lab Leukemia Diagnost, D-81377 Munich, Germany
关键词
chronic myeloproliferative diseases; CMPD; cytogenetics; routine diagnostics;
D O I
10.1007/s00277-004-0977-1
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
In chronic myeloproliferative disorders other than CML (CMPD) recurrent cytogenetic abnormalities occur, but specific patterns of chromosomal aberrations in the specific entities have so far not been detected. Thus, the value of conventional cytogenetics in the routine diagnostic setting of CMPD remains to be clarified. We performed a cytogenetic study on 409 patients with different CMPD [polycythemia vera, essential thrombocytosis (ET), idiopathic osteomyelofibrosis, chronic myelomonocytic leukemia (proliferative subtype), idiopathic hypereosinophilic syndrome (HES), myeloproliferative syndrome (unclassifiable)] and on 102 patients with suspected CMPD. Cytogenetic abnormalities occurred in different frequencies ranging from 3 to 40% depending on the subtype, and showed some specific differences with respect to their type. The highest frequency and the most complex pattern of clonal aberrations were observed in idiopathic osteomyelofibrosis. However, clonal aberrations were also found in 10% of patients with suspected CMPD establishing the diagnosis of a malignant disease. In conclusion, cytogenetics are essential in the routine diagnostic setting of CMPD or cases suspicious for CMPD. In ET and in HES the aberration rate was only 3 and 7%, respectively. Thus, cytogenetics can be omitted. However, in some of these cases molecular procedures should be integrated into the routine diagnostic process.
引用
收藏
页码:250 / 257
页数:8
相关论文
共 21 条
[1]
ADEWALE A, 2003, HEMATOL ONCOL CLIN N, V17, P1129
[2]
Myeloproliferative disorders [J].
Bench, AJ ;
Cross, NCP ;
Huntly, BJP ;
Nacheva, EP ;
Green, AR .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2001, 14 (03) :531-551
[3]
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].
Cools, J ;
DeAngelo, DJ ;
Gotlib, J ;
Stover, EH ;
Legare, RD ;
Cortes, J ;
Kutok, J ;
Clark, J ;
Galinsky, I ;
Griffin, JD ;
Cross, NCP ;
Tefferi, A ;
Malone, J ;
Alam, R ;
Schrier, SL ;
Schmid, J ;
Rose, M ;
Vandenberghe, P ;
Verhoef, G ;
Boogaerts, M ;
Wlodarska, I ;
Kantarjian, H ;
Marynen, P ;
Coutre, SE ;
Stone, R ;
Gilliland, DG .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214
[4]
Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate [J].
Coutré, S ;
Gotlib, J .
SEMINARS IN CANCER BIOLOGY, 2004, 14 (01) :23-31
[5]
Tyrosine kinase fusion genes in chronic myeloproliferative diseases [J].
Cross, NCP ;
Reiter, A .
LEUKEMIA, 2002, 16 (07) :1207-1212
[6]
Mechanisms of disease - Chronic myeloid leukemia - Advances in biology and new approaches to treatment [J].
Goldman, JM ;
Melo, JV .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1451-1464
[7]
Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients [J].
Herishanu, Y ;
Lishner, M ;
Bomstein, Y ;
Kitay-Cohen, Y ;
Fejgin, MD ;
Gaber, E ;
Amiel, A .
CANCER GENETICS AND CYTOGENETICS, 2001, 128 (02) :154-157
[8]
JAFFE E, 2001, TUMORS HAEMATOPOIETC
[9]
Cytogenetic and molecular genetic evolution of chronic myeloid leukemia [J].
Johansson, B ;
Fioretos, T ;
Mitelman, F .
ACTA HAEMATOLOGICA, 2002, 107 (02) :76-94
[10]
Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis [J].
Klippel, S ;
Strunck, E ;
Temerinac, S ;
Bench, AJ ;
Meinhardt, G ;
Mohr, U ;
Leichtle, R ;
Green, AR ;
Griesshammer, M ;
Heimpel, H ;
Pahl, HL .
BLOOD, 2003, 102 (10) :3569-3574